AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap

AbbVie's golden cross is widening with a 2.8% dividend yield, while Baxter's razor-thin cross sits atop a still-declining 200-day moving average.

Baxter eliminated its dividend and posted -$900 million net income in FY2025, disqualifying it for any income-focused retirement portfolio.

Skyrizi and Rinvoq grew 31% and 23% in Q1 2026, more than offsetting Humira's biosimilar losses and driving AbbVie's full-year guidance raise.

This lithium producer surpassed a $1B private valuation, joining some of America's most powerful startups. Now you can invest in EnergyX alongside global giants like General Motors, but only through July 16. (sponsor)

Both AbbVie ( NYSE:ABBV ) and Baxter International ( NYSE:BAX ) flashed the same technical signal this month: a golden cross, where the 50-day moving average pushed above the 200-day. The retirement question is simple: which one belongs in an income-focused portfolio right now?

AbbVie's cross, formed around July 7, is clean and widening: the 50-day is 222.91 versus a 200-day of 222.66, with both lines rising. Baxter's cross is a different picture. The 50-day at 19.85 is only fractionally above a 200-day at 19.26, and the 200-day is still declining. Remember that golden crosses are lagging momentum indicators. They say nothing about cash flow or dividend safety. So the verdict has to come from fundamentals.

AbbVie just declared its $1.73 quarterly payout, with an ex-dividend date of July 15, 2026, and payment on August 14, 2026. That annualizes to $6.92, extending a 13-year streak of increases dating to the 2013 Abbott spinoff, with the most recent hike a 5.5% bump. At the current price of $244.78, that represents a yield near 2.8%.

Baxter is the opposite story. Management slashed the quarterly dividend to $0.01 alongside Q4 2025 results, effectively eliminating the payout. Annualized, that is $0.04 per share.

The winner is AbbVie, decisively. Retirees writing checks from portfolio income cannot use a token dividend.

July 16 is the Final Day to Tap Into the Lithium Boom (sponsor) General Motors, POSCO, and 50,000+ everyday investors have already backed lithium producer EnergyX .

Here's why you should do the same before their July 16 investment deadline: lithium prices are up 75% this year, with demand projected to grow a staggering 5X by 2040.

With tech that can recover up to 3X more lithium than traditional methods, EnergyX is preparing to unlock up to 15M+ tons. Become a private-stage EnergyX investor before the July 16 deadline .

AbbVie is a $432.5 billion mega-cap with TTM revenue of $62.82 billion, an operating margin of 26.6%, and a beta of 0.283, roughly one-quarter of the market's volatility. Yes, book value is negative from buyback and Allergan-era leverage, but cash generation covers the dividend comfortably.

Baxter carries a market cap of just $11.3 billion, TTM EPS of −$1.91, and a profit margin of −9.7%. FY 2025 GAAP net income was −$900 million after $485 million in goodwill impairments and $290 million in intangible impairments. Q1 2026 revenue increased 2.9% year over year, while adjusted EPS dropped roughly 35%.

AbbVie's immunology franchise is doing the heavy lifting. Skyrizi grew 30.9% to $4.48 billion, and Rinvoq rose 23.3% to $2.12 billion in Q1 2026, more than offsetting Humira's 38.6% biosimilar erosion. With the Q1 report, management raised full-year adjusted EPS guidance to $14.08 to $14.28. The consensus price target of $265.50 compares with the most recent close at $244.78.

Baxter's 2026 guidance calls for reported sales flat to up 1% and adjusted EPS of $1.85 to $2.05, a step-down from $2.27. Overhangs include the Novum IQ LVP pump shipment hold, tariff pressure, and the reset following the January 2025 Kidney Care sale to Carlyle. New CEO Andrew Hider only took over in September 2025. The $21.71 analyst consensus target is a bit less than the current price.

AbbVie wins across all three dimensions that matter for a retirement portfolio: a growing, well-covered dividend, mega-cap balance sheet stability with a low 0.28 beta, and a double-digit growth engine that has already prompted a guidance raise. The stock has returned 27.8% over the past year and 478.9% over 10 years, including reinvested momentum.